Humacyte (NASDAQ:HUMA) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.11) by 18.18 percent. This is a 10 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $495.000 thousand which missed the analyst consensus estimate of $1.455 million by 65.98 percent. This is a 4.26 percent decrease over sales of $517.000 thousand the same period last year.